Cardioprotection with adenosine-regulating agent, GP531: Effects on no-reflow, infarct size, and blood flow following ischemia/ reperfusion in the rabbit

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 15, Issue 1, 2010, Pages 60-67

  Hale, Sharon L ^a   Kloner, Robert A ^a,b  

^a GOOD SAMARITAN HOSPITAL   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Adenosine regulating agent; GP531; Myocardial infarct size; No reflow

Indexed keywords

[5 AMINO 1 BETA D(5 BENZYLAMINO 5 DEOXYRIBOFURANOSYL)IMIDAZOLE 4 CARBOXAMIDE]; ADENOSINE; AMIDE; GP 531; MICROSPHERE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG MEGADOSE; EXPERIMENTAL RABBIT; HEART INFARCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE BLOOD FLOW; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART PROTECTION; HEART RATE; LOADING DRUG DOSE; LOW DRUG DOSE; MALE; MEAN ARTERIAL PRESSURE; NITROBLUE TETRAZOLIUM TEST; NONHUMAN; PRIORITY JOURNAL; REPERFUSION; SYSTOLIC BLOOD PRESSURE;

ADENOSINE; AMINOIMIDAZOLE CARBOXAMIDE; ANALYSIS OF VARIANCE; ANIMALS; DEOXYRIBONUCLEOSIDES; DISEASE MODELS, ANIMAL; HEMODYNAMICS; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; RABBITS; RANDOM ALLOCATION;

EID: 76649144467     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248409357742     Document Type: Article

References (21)

1. Engler RL Harnessing nature's own cardiac defense mechanism with acadesine, an adenosine regulating agent: importance of the endothelium. J Card Surg. 1194 ; 9 (3 suppl). 482-492.
2. Gruber HE, Hoffer ME, McAllister DR, et al. Increased adenosine concentration in blood from ischemic myocardium by AICA riboside. Effects on flow, granulocytes, and injury. Circulation. 1989 ; 80 (5). 1400-1411.
3. Mangano DT, Miao Y., Tudor IC, Dietzel C. for the Investigators of the Multicenter Study of Perioperative Ischemia (McSPI) Research Group ; Ischemia Research and Education Foundation (IREF). Post-reperfusion myocardial infarction: long-term survival improvement using adenosine regulation with acadesine. J Am Coll Cardiol. 2006 ; 48 (1). 206-214.
4. Kurz MA, Bullough DA, Bugg CJ, Mullane KM, Young MA Cardioprotection with a novel adenosine regulating agent mediated by intravascular adenosine. Eur J Pharmacol. 1991 ; 322 (2-3). 211-220.
5. Kloner RA, Ganote CE, Jennings RB "The no-reflow quot; phenomenon following temporary coronary artery occlusion in the dog. Clin Invest. 1974 ; 54 (6). 1496-1508.
6. Ambrosio G., Weisman HF, Mannisi JA, Becker LC Progressive impairment of regional myocardial perfusion after initial restoration of postischemic blood flow. Circulation. 1989 ; 80 (6). 1846-1861.
7. Reffelmann T., Hale SL, Li G., Kloner RA Relationship between no reflow and infarct size as influenced by the duration of ischemia and reperfusion. Am J Physiol. 2001; 282 (2). H766 - H772.
8. Ito H., Komura N., Iwakura K., Kawano S., Okamura A., Fujii K. Combination study of myocardial perfusion and left ventricular filling provides an excellent prediction of clinical outcomes in patients with reperfused myocardial infarction. Basic Res Cardiol. 2006 ; 101 (5). 400-407.
9. Rasband WS Image J. Bethesda, MD: National Institutes of Health, 1997-2007. http://rsb.info.nih.gov/ij/. Accessed January 11, 2010.
10. Claeys MJ, Bosmans J., De Ceuninck M., et al. Effect of intracoronary adenosine infusion during coronary intervention on myocardial reperfusion injury in patients with acute myocardial infarction. Am J Cardiol. 2004 ; 94 (1). 9-13.
11. Kloner RA, Forman MB, Gibbons RJ, Ross AM, Alexander RW, Stone GW Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur Heart J. 2006 ; 27 (20). 2376-2377.
12. Marzilli M., Orsini E., Marraccini P., Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation. 2000 ; 101 (18). 2154-2159.
13. Quintana M., Hjemdahl P., Sollevi A., et al, for the ATTACC Investigators. Left ventricular function and cardiovascular events following adjuvant therapy with adenosine in acute myocardial infarction treated with thrombolysis, results of the ATTenuation by Adenosine of Cardiac Complications (ATTACC) study. Eur J Clin Pharmacol. 2003 ; 59 (1). 1-9.
14. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW for the AMISTAD-II Investigators. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol. 2005 ; 45 (11). 1775-1780.
15. Kingma JG Jr, Simard D., Rouleau JR Timely administration of AICA riboside reduces reperfusion injury in rabbits. Cardiovasc Res. 1994 ; 28 (7). 1003-1007.
16. Zhao ZQ, Williams MW, Sato H., et al. Acadesine reduces myocardial infarct size by an adenosine mediated mechanism. Cardiovasc Res. 1995 ; 29 (4). 495-505.
17. Menasche P., Jamieson WR, Flameng W., Davies MK Acadesine: a new drug that may improve myocardial protection in coronary artery bypass grafting. Results of the first international multicenter study. Multinational Acadesine Study Group. J Thorac Cardiovasc Surg. 1995 ; 110 (4 pt 1). 1096-1106.
18. Dorion M., Roleau J., Kingma JG Jr. Failure of AICA riboside to limit infarct size during acute myocardial infarction in rabbits. J Cardiovasc Pharmacol. 1992 ; 19 (1). 69-77.
19. Tsuchida A., Liu GS, Mullane K., Downey JM Acadesine lowers temporal threshold for the myocardial infarct size limiting effect of preconditioning. Cardiovase Res. 1993 ; 27 (1). 116-120.
20. Galinanes M., Mullane KM, Bullough D., Hearse DJ Acadesine and myocardial protection. Studies of time of administration and dos-response in the rat. Circulation. 1992 ; 86 (2). 598-608.
21. Sabbah HN, Wang M., Ilsar I., Jiang A., Sabbah MS, Gupta RC Intravenous GP531, an adenosine regulating agent, improves left ventricular function in dogs with chronic advanced heart failure. Eur J Heart Failure. 2009 ; 8 (suppl 2 ):Abstract 144.